Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

Core Insights - Conduit Pharmaceuticals has appointed Simon Fry to its Board of Directors, bringing over 30 years of investment banking experience to the company [2][4] - Fry's expertise in capital markets and strategic asset management is expected to enhance Conduit's growth objectives and strategic initiatives [4][5] Company Overview - Conduit Pharmaceuticals is a multi-asset, clinical stage, disease-agnostic life science company focused on efficient compound development [5] - The company acquires and funds the development of Phase 2-ready assets, aiming for exits through third-party license deals after successful clinical trials [5] Leadership Background - Simon Fry has held senior executive positions at top-tier institutions, including CEO at Crosby Asset Management and Managing Director at Nomura [3] - At Nomura, Fry initiated the Asset Investment Group and was responsible for building the International Markets Division [3] - He also spent 14 years at Credit Suisse First Boston, where he developed the Asset Trading Group [3] Board Committees - Fry is expected to serve on both the Audit Committee and the Compensation Committee upon his appointment [4]